Organ preservation for patients with anterior mucosal squamous cell carcinoma of the nasal cavity: Rhinectomy‐free survival in those refusing surgery

Background: We performed a comparative analysis between an organ-preservation protocol and surgery followed by radiotherapy in patients with locally advanced squamous cell carcinoma of the larynx and hypopharynx; Methods: 60 previously untreated patients who were treated with induction chemotherapy followed by chemoradiotherapy in responders were compared with a control group of 60 patients treated with up-front surgery. Both groups were statistically comparable, according to the subsite, TNM (tumor-node-metastasis) stage, age, and sex; Results: Mean age was 58 years and 92% were male. No significant statistical difference was observed for overall survival (OS) (HR 0.75; 95% CI 0.48–1,18; P = 0.22) and disease-specific survival (DSS) (HR 0.98; 95% CI 0.52–1.83, P = 0.96). Also, there was no significant difference for recurrence-free survival (HR 0.931; 95% CI 0.57–1.71; P = 0.81), metastases-free survival (HR 2.23; 95% CI 0.67–7.41; P = 0.19), and the appearance of second primary tumors (HR 1.22; 95% CI 0.51–2.88; P = 0.64); Conclusions: The results of the organ-preservation approach did not appear inferior to those of surgery plus (chemo)radiotherapy for patients with T3/T4a larynx and T2–T4a hypopharynx cancer with respect to OS and DSS, locoregional control and metastases-free survival.

Download Full-text

A clinical study of multimodal treatment for orbital organ preservation in locally advanced squamous cell carcinoma of the nasal cavity and paranasal sinus

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyw064 ◽

2016 ◽

Vol 46 (8) ◽

pp. 727-734 ◽

Cited By ~ 11

Author(s):

Nan-xiang Chen ◽

Lei Chen ◽

Jia-ling Wang ◽

Jin-yuan Wang ◽

Fang Yan ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Clinical Study ◽

Nasal Cavity ◽

Cell Carcinoma ◽

Paranasal Sinus ◽

Squamous Cell ◽

Organ Preservation ◽

Multimodal Treatment ◽

Locally Advanced ◽

Advanced Squamous Cell Carcinoma

Download Full-text

Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation

The Korean Journal of Internal Medicine ◽

10.3904/kjim.2015.020 ◽

2016 ◽

Vol 31 (3) ◽

pp. 570-578 ◽

Cited By ~ 13

Author(s):

Chan-Young Ock ◽

Bhumsuk Keam ◽

Tae Min Kim ◽

Doo Hee Han ◽

Tae-Bin Won ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Nasal Cavity ◽

Cell Carcinoma ◽

Head And Neck ◽

Paranasal Sinus ◽

Induction Chemotherapy ◽

Squamous Cell ◽

Organ Preservation ◽

Neck Squamous Cell Carcinoma

Download Full-text

Role of Neck Dissection in Organ-Preservation for Glottic Squamous Cell Carcinoma

Indian Journal of Otolaryngology and Head & Neck Surgery ◽

10.1007/s12070-021-02470-7 ◽

2021 ◽

Author(s):

Kuauhyama Luna-Ortiz ◽

Nancy Reynoso-Noverón ◽

Luis C. Zacarías-Ramón ◽

Zelik Luna-Peteuil ◽

Dorian Y. García-Ortega

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Neck Dissection ◽

Squamous Cell ◽

Organ Preservation

Download Full-text

Genomic heterogeneity and copy number variant burden are associated with poor recurrence‐free survival and 11q loss in human papillomavirus‐positive squamous cell carcinoma of the oropharynx

Cancer ◽

10.1002/cncr.33504 ◽

2021 ◽

Author(s):

Travis P. Schrank ◽

Nicholas Lenze ◽

Lee P. Landess ◽

Alan Hoyle ◽

Joel Parker ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Human Papillomavirus ◽

Cell Carcinoma ◽

Squamous Cell ◽

Copy Number ◽

Copy Number Variant ◽

Recurrence Free Survival ◽

Free Survival

Download Full-text

Anal squamous cell carcinoma in a high HIV prevalence population

Discover Oncology ◽

10.1007/s12672-021-00397-7 ◽

2021 ◽

Vol 12 (1) ◽

Author(s):

Danielle R. L. Brogden ◽

Christopher C. Khoo ◽

Christos Kontovounisios ◽

Gianluca Pellino ◽

Irene Chong ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Disease Free Survival ◽

Hiv Positive ◽

Anal Squamous Cell Carcinoma ◽

Free Survival ◽

Persons Living With Hiv ◽

Disease Free ◽

Hiv Negative

AbstractAnal Squamous Cell Carcinoma (ASCC) is a rare cancer that has a rapidly increasing incidence in areas with highly developed economies. ASCC is strongly associated with HIV and there appears to be increasing numbers of younger male persons living with HIV (PLWH) diagnosed with ASCC. This is a retrospective cohort study of HIV positive and HIV negative patients diagnosed with primary ASCC between January 2000 and January 2020 in a demographic group with high prevalence rates of HIV. One Hundred and seventy six patients were included, and clinical data was retrieved from multiple, prospective databases. A clinical subgroup was identified in this cohort of younger HIV positive males who were more likely to have had a prior diagnosis of Anal Intraepithelial Neoplasia (AIN). Gender and HIV status had no effect on staging or disease-free survival. PLWH were more likely to develop a recurrence (p < 0.000) but had a longer time to recurrence than HIV negative patients, however this was not statistically significant (46.1 months vs. 17.5 months; p = 0.077). Patients known to have a previous diagnosis of AIN were more likely to have earlier staging and local tumour excision. Five-year Disease-Free Survival was associated with tumour size and the absence of nodal or metastatic disease (p < 0.000).

Download Full-text

Epigenetic Alterations Associated with the Overall Survival and Recurrence Free Survival among Oral Squamous Cell Carcinoma Patients

Journal of Clinical Medicine ◽

10.3390/jcm9041035 ◽

2020 ◽

Vol 9 (4) ◽

pp. 1035 ◽

Cited By ~ 1

Author(s):

Yasmen Ghantous ◽

Aysar Nashef ◽

Imad Abu-Elnaaj

Keyword(s):

Overall Survival ◽

Squamous Cell Carcinoma ◽

Oral Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Clinical Features ◽

Squamous Cell ◽

Methylation Status ◽

Recurrence Free Survival ◽

Epigenetic Alterations ◽

Free Survival

Oral squamous cell carcinoma (OSCC) is a fatal disease caused by complex interactions between environmental, genomic, and epigenetic alterations. In the current study, we aimed to identify clusters of genes whose promoter methylation status correlated with various tested clinical features. Molecular datasets of genetic and methylation analysis based on whole-genome sequencing of 159 OSCC patients were obtained from the The Cancer Genome Atlas (TCGA) data portal. Genes were clustered based on their methylation status and were tested for their association with demographic, pathological, and clinical features of the patients. Overall, seven clusters of genes were revealed that showed a significant association with the overall survival/recurrence free survival of patients. The top ranked genes within cluster 4, which showed the worst prognosis, primarily acted as paraneoplastic genes, while the genes within cluster 6 primarily acted as anti-tumor genes. A significant difference was found regarding the mean age in the different clusters. No significant correlation was found between the tumor staging and the different clusters. In conclusion, our result provided a proof-of-principle for the existence of phenotypic diversity among the epigenetic clusters of OSCC and demonstrated the utility of the use epigenetics alterations in devolving new prognostic and therapeutics tools for OSCC patients.

Download Full-text

Hyperfractionated Radiation Therapy With or Without Concurrent Low-Dose Daily Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Prospective Randomized Trial

Journal of Clinical Oncology ◽

10.1200/jco.2000.18.7.1458 ◽

2000 ◽

Vol 18 (7) ◽

pp. 1458-1464 ◽

Cited By ~ 345

Author(s):

Branislav Jeremic ◽

Yuta Shibamoto ◽

Biljana Milicic ◽

Nebojsa Nikolic ◽

Aleksandar Dagovic ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Radiation Therapy ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Low Dose ◽

Locally Advanced ◽

Progression Free Survival ◽

High Grade ◽

Free Survival

PURPOSE: To investigate whether the addition of cisplatin (CDDP) to hyperfractionation (Hfx) radiation therapy (RT) offers an advantage over the same Hfx RT given alone in locally advanced (stages III and IV) squamous cell carcinoma of the head and neck. PATIENTS AND METHODS: One hundred thirty patients were randomized to receive either Hfx RT alone to a tumor dose of 77 Gy in 70 fractions in 35 treatment days over 7 weeks (group I, n = 65) or the same Hfx RT and concurrent low-dose (6 mg/m2) daily CDDP (group II, n = 65). RESULTS: Hfx RT/chemotherapy offered significantly higher survival rates than Hfx RT alone (68% v 49% at 2 years and 46% v 25% at 5 years; P = .0075). It also offered higher progression-free survival (46% v 25% at 5 years; P = .0068), higher locoregional progression-free survival (LRPFS) (50% v 36% at 5 years; P = .041), and higher distant metastasis-free survival (DMFS) (86% v 57% at 5 years; P = .0013). However, there was no difference between the two treatment groups in the incidence of either acute or late high-grade RT-induced toxicity. Hematologic high-grade toxicity was more frequent in group II patients. CONCLUSION: As compared with Hfx RT alone, Hfx RT and concurrent low-dose daily CDDP offered a survival advantage, as well as improved LRPFS and DMFS.

Download Full-text